Teladoc Health (NYSE:TDOC) Hits New 12-Month Low at $13.54

Teladoc Health, Inc. (NYSE:TDOC)’s share price hit a new 52-week low during trading on Monday . The stock traded as low as $13.54 and last traded at $13.57, with a volume of 3128879 shares changing hands. The stock had previously closed at $14.21.

Analyst Ratings Changes

TDOC has been the topic of a number of research reports. DA Davidson dropped their target price on shares of Teladoc Health from $22.00 to $18.00 and set a “neutral” rating on the stock in a report on Wednesday, February 21st. Citigroup lowered their target price on shares of Teladoc Health from $21.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, February 21st. Leerink Partnrs reissued a “market perform” rating on shares of Teladoc Health in a research report on Monday, February 26th. Piper Sandler lowered their price objective on Teladoc Health from $30.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, February 21st. Finally, Truist Financial cut their target price on Teladoc Health from $23.00 to $17.00 and set a “hold” rating on the stock in a research note on Wednesday, March 6th. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $22.23.

Teladoc Health Stock Up 0.9 %

The company’s 50-day simple moving average is $16.02 and its two-hundred day simple moving average is $18.02. The firm has a market capitalization of $2.24 billion, a P/E ratio of -9.80 and a beta of 0.94. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.54 and a quick ratio of 3.47.

Teladoc Health (NYSE:TDOC) last released its earnings results on Tuesday, February 20th. The health services provider reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.05. The company had revenue of $660.50 million for the quarter, compared to the consensus estimate of $670.79 million. Teladoc Health had a negative return on equity of 9.22% and a negative net margin of 8.47%. Teladoc Health’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.23) earnings per share. As a group, research analysts expect that Teladoc Health, Inc. will post -1.07 earnings per share for the current year.

Insider Buying and Selling at Teladoc Health

In other Teladoc Health news, CMO Stephany Verstraete sold 7,945 shares of the stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $115,361.40. Following the completion of the sale, the chief marketing officer now directly owns 56,486 shares of the company’s stock, valued at approximately $820,176.72. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Teladoc Health news, insider Laizer Kornwasser sold 7,882 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $19.18, for a total transaction of $151,176.76. Following the completion of the transaction, the insider now owns 57,223 shares in the company, valued at approximately $1,097,537.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CMO Stephany Verstraete sold 7,945 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $115,361.40. Following the sale, the chief marketing officer now directly owns 56,486 shares in the company, valued at $820,176.72. The disclosure for this sale can be found here. Insiders have sold a total of 134,441 shares of company stock valued at $2,025,041 over the last ninety days. 1.63% of the stock is currently owned by company insiders.

Institutional Trading of Teladoc Health

A number of large investors have recently made changes to their positions in TDOC. MetLife Investment Management LLC purchased a new position in shares of Teladoc Health during the 1st quarter worth about $218,000. Panagora Asset Management Inc. raised its holdings in shares of Teladoc Health by 18.8% in the first quarter. Panagora Asset Management Inc. now owns 16,710 shares of the health services provider’s stock worth $1,205,000 after buying an additional 2,640 shares during the period. Rhumbline Advisers lifted its stake in shares of Teladoc Health by 2.3% during the 1st quarter. Rhumbline Advisers now owns 130,916 shares of the health services provider’s stock worth $9,443,000 after acquiring an additional 2,921 shares during the last quarter. Great West Life Assurance Co. Can boosted its holdings in Teladoc Health by 10.8% during the 1st quarter. Great West Life Assurance Co. Can now owns 107,908 shares of the health services provider’s stock valued at $8,237,000 after acquiring an additional 10,559 shares during the period. Finally, Raymond James Trust N.A. grew its position in Teladoc Health by 7.8% in the 1st quarter. Raymond James Trust N.A. now owns 11,451 shares of the health services provider’s stock valued at $826,000 after acquiring an additional 827 shares during the last quarter. 76.82% of the stock is currently owned by institutional investors.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.